Quintrio
Home

SERVICES-MANAGEMENT CONSULTING SERVICES

Nordicus Partners Corporation Common Stock

NORD

Nordicus Partners Corp specializes in developing breakthrough therapeutics for diseases with unmet medical needs. The Company focuses on acquiring and developing drugs from biotech companies in the Nordics, a region known for its scientists, life sciences ecosystem, and drug discoveries and developments. Its current portfolio includes the preclinical biotechnology companies Orocidin A/S, Bio-Convert A/S, and NoviThera ApS. The Company is dedicated to developing breakthrough therapeutics in diseases with unmet medical needs, starting with oral disorders. It operates in the segment focused on developing medicines supporting oral health.

Last trade $0.00
Day change $0.00 (0.00%)
Day range $2.48 – $3.15
Volume 8,968
Market cap $57M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

No ratio data was found for NORD.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

No quarterly income statement data was found for NORD.

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Nordicus Partners Corporation Corporate Update

Nordicus Partners announced positive preclinical results for its subsidiary Orocidin's QR-01 treatment for aggressive periodontitis, demonstrating efficacy in both beagle and rat studies with reduced bone loss confirmed by micro-CT imaging. Phase IIa clinical trials are planned for H1 2027 at the University of Copenhagen. Bio-Convert received a toxicity waiver for QR-02 (oral leukoplakia treatment) with GMP manufacturing on track for December 2026, while NoviThera established biological proof of concept for QR-04 psoriasis treatment. The company's Nasdaq uplisting application remains under active review.

GlobeNewswire Inc.

Orocidin and Syngene Partner to Accelerate Biotech Innovation

Orocidin, a subsidiary of Nordicus Partners Corporation, has announced a strategic partnership with Syngene International to advance Orocidin's QR-01 peptide program. The partnership will leverage Syngene's expertise in GMP peptide development and manufacturing to support Orocidin's efforts to bring new drugs to market faster and more reliably.

GlobeNewswire Inc.

Nordicus Partners Corporation Enters Into A Consultancy Agreement With BIO-CONVERT In Denmark

Beverly Hills, California., June 21, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, today announced it entered into a Consultancy Agreement with BIO-CONVERT in Denmark.

GlobeNewswire Inc.

Orocidin – New Insights Into The Treatment Of Periodontitis

Beverly Hills, California., June 11, 2024 (GLOBE NEWSWIRE) -- Nordicus Partners Corporation (OTCQB: NORD) (“Nordicus” or the “Company”), a financial consulting company specializing in providing Nordic and U.S. life sciences companies with optimal conditions to establish themselves on the U.S. market, and its 95% owned subsidiary, Orocidin A/S (“Orocidin”), announced today new insights into the treatment of periodontitis.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Apr 24, 2020$1.80Apr 23, 2020special

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Nov 8, 20241-for-10reverse split